Predicted cardiac and second cancer risks for patients undergoing VMAT for mediastinal Hodgkin lymphoma.
Orla Anne HoulihanGeorgios NtentasDavid J CutterPatricia DalyCharles GillhamOrla McArdleFrances K DuanePublished in: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico (2022)
For patients with mediastinal lymphoma excess mortality risks from CVD and second cancers remain clinically significant despite contemporary chemotherapy and photon-RT. Efforts to reduce the toxicity of combined modality treatment, for example, using DIBH, reduced margins and advanced RT, e.g. proton beam therapy, should be continued to further reduce potentially fatal treatment effects.